80mg vial
KLOW is a research-grade compounded blend combining four complementary peptides - KPV (anti-inflammatory tripeptide), Larazotide (tight-junction modulator), Orexin-A (wakefulness and metabolic regulator) and GHK-Cu (regenerative copper tripeptide). Designed as a single-injection regenerative stack, it is studied primarily for gut-barrier integrity, systemic inflammation and skin/connective remodelling.
Checking availability…
GHK-Cu drives collagen synthesis and broad transcriptomic remodelling. Larazotide antagonises zonulin to tighten intestinal tight junctions. KPV provides α-MSH–derived anti-inflammatory activity via NF-κB suppression. Orexin-A modulates wakefulness, appetite and energy expenditure via OX1R/OX2R receptors.
Common research protocols use 200–500mcg of the blend subcutaneously once daily, typically morning administration due to the orexin component. Cycles run 4–8 weeks.
Variable across constituents - GHK-Cu approx. 1 hour, KPV short, Larazotide local GI activity, Orexin-A approx. 30–60 minutes plasma.
Reconstitute an 80mg vial with 4–5mL bacteriostatic water for approx. 16–20mg/mL working concentration. Swirl gently; the solution may appear faintly tinted due to the copper component.
Lyophilised: 2–8°C, stable 12–18 months. Reconstituted: 2–8°C, protect from light, use within 30 days.